Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association
Open Access
- 1 July 2017
- journal article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 11 (4) , 891-900
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial HypercholesterolemiaJACC, 2016
- Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agentsEuropean Heart Journal, 2016
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2Journal of Clinical Lipidology, 2015
- National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summaryJournal of Clinical Lipidology, 2014
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsCirculation, 2014
- An assessment by the Statin Intolerance Panel: 2014 updateJournal of Clinical Lipidology, 2014
- PCSK9Circulation Research, 2014
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyEuropean Heart Journal, 2013
- Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin usersJournal of Clinical Lipidology, 2012